Entest BioMedical (OTCBB: ENTB) - Up to $2.0 million in potential annual revenues

Entest BioMedical Inc. (OTCBB: ENTB) has signed a letter of intent (LOI) to acquire three veterinary hospitals located in Southern California. These three veterinary hospitals are sister businesses which Entest has been informed generated a combined historic revenue stream of $900,000 per year.

David Koos, CEO of Entest, stated yesterday in a press release:

"Based on historical performance, the successful acquisition of these three hospitals could result in a potential $900,000 per year increase in our overall revenue. This veterinary hospital group's three Orange County area facilities are located in extremely affluent communities whose strong economic base should support business expansion."

Mr. Koos also noted the potential revenue stream from the three hospitals combined with potential revenue from an unrelated previously disclosed pending acquisition "could put Entest on pace to produce $2 million per year in revenue once these transactions are closed."

This acquisition follows on from a press release earlier in the month when Entest announced the Company has entered into escrow on the proposed purchase of a veterinary hospital located in Southern California.

Mr. Koos stated at that time:

"I'm excited about this potential acquisition. Not only does it represent a second spoke in our distribution wheel for ImenVax™ and other potential products but we believe it should bring us approximately $500,000 per year in near term revenue. We have already acquired the McDonald Animal Hospital and, once this new acquisition is made, we expect our near term revenue from these two veterinary hospitals to exceed $1.1 million on an annualized basis."

ImenVax™ is an immuno-therapeutic cancer vaccine for dogs currently under development by Entest. The Company recently announced the initiation of a collaboration with RenovoCyte LLC and Medistem Inc. to explore the development of a stem cell therapy for treating hip dysplasia in dogs..

Entest has increased the number of veterinarians at the McDonald Animal Hospital ("MAH") located in Santa Barbara, California, and has begun an aggressive marketing campaign in the Santa Barbara area to create public awareness of MAH's involvement with stem cell therapy for animals and immuno-therapeutic cancer vaccines for dogs. Entest acquired the McDonald Animal Hospital on January 4, 2011.

Entest BioMedical (OTCBB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.



Entest (OTBB: ENTB) Stem Cell Therapy for Treating Canine Hip Dysplasia

Difficult to prevent and treat, canine hip dysplasia is among the most studied and the most frustrating diseases in veterinary medicine.  Canine hip dysplasia is a developmental orthopedic disease in which an abnormal formation of the hip leads to looseness in the hip joints, causing cartilage damage.  Progressive arthritis can result, and when it does, it can be crippling. 

• One out of every four dogs will get hip dysplasia;
• Entest and RenovoCyte are researching the use of Medistem's Canine Endometrial Regenerative Cells (CERCs) as part of a treatment for canine hip dysplasia;
• Entest's McDonald Animal Hospital will serve as clinical base for studies.

Entest BioMedical Inc. (OTCBB: ENTB) announced last week their collaboration with RenovoCyte LLC and Medistem Inc. to explore the development of a stem cell therapy for treating hip dysplasia in dogs.

Pfizer pioneered the market for dog painkillers when it introduced Rimadyl in 1997. Nearly 15 million dogs have taken it, many for pain from degenerative joint disease, or osteoarthritis. Rimadyl now has four competitors with more likely. The market for dog arthritis pain medications tops $130 million a year and is growing about 13% a year, consulting firm Wood Mackenzie says.

Entest's Chairman & CEO, David Koos, stated in the press release:

"Our Company is extremely excited about clinically applying Medistem's Canine Endometrial Regenerative Cells (CERCs) and RenovoCyte's Investigational New Animal Drug (INAD) protocols at our McDonald Animal Hospital. Entest views this collaboration as a major step in developing veterinary therapeutics that increase the quality of life for our pets."

Both RenovoCyte's CEO Dr. Erik Woods and Medistem's Chairman Vladimir Bogin, M.D., stated they anticipate these CERCs will reduce the inflammation and the degenerative nature of hip dysplasia in dogs.

Entest noted that once efficacy is demonstrated in treating hip dysplasia, the door will be wide open for collaboration to expand its focus to treating other veterinary conditions that are lacking a good treatment model. The Entest BioMedical model continues to focus on the development of regenerative and immunological therapies for veterinary applications. ENTB is focused on:

• Veterinary therapies that harness the animal's own reparative and immunological mechanisms.
• An immuno-therapeutic cancer vaccine for canines (ImenVax™).
• Acquiring veterinary hospitals as both a source of near term revenue and as a distribution channel for its veterinary therapies and treatments. As part of this mission, Entest purchased the McDonald Animal Hospital on January 4, 2011, which serves to both generate revenue and provide the initial part of Entest's distribution channel.

Trade Alert - Entest BioMedical (OTCBB: ENTB) closes above $4.00

The Company put out a press release last week informing investors of updates on "Veterinary Clinic Acquisitions, Business Expansion and ImenVax(TM) Safety Study."

In the release, Entest BioMedical David Koos covered a number of updates:,

• The acquisition of McDonald Animal Hospital by ENTB was closed;
• Entest is examining two more veterinary facilities that have a combined annual revenue of $1.5 million with room for expansion."
• The McDonald facility is in the process of adding additional veterinarians, developing advertising campaigns to drive business, expanding the hours of operation and providing emergency services on weekends. Koos stated that he expects "to double the revenue at MAH over the next 18 months."
• Jennifer Hammervold is the new Director of Veterinary Practice Management. She will oversee future acquisition candidates and coordinate their integration into the Company.  
• Entest is currently recruiting dogs with cancer to participate in the ImenVax™ 10 Dog Safety Study. ImenVax™ is an immuno-therapeutic cancer vaccine being developed for dogs. Everyone involved with this research is anticipating strong results in the treatment of oral melanoma.

Since that announcement, the ENTB stock has made a steady climb to yesterday's close at $4.07.

Full Waterville Research report on ENTB.

Flash Player 9 or higher is required to view the chart
Click here to download Flash Player now

View the full ENTB chart at Wikinvest

Entest BioMedical (OTCBB: ENTB) makes a Move after acquisition

Entest BioMedical (OTCBB: ENTB) closed today at $3.50 and the stock was traded below $1.50 before the end of 2010. So what happened?

Flash Player 9 or higher is required to view the chart
Click here to download Flash Player now

View the full ENTB chart at Wikinvest

Entest announced the acquisition of the McDonald Animal Hospital (MAH) in Santa Barbara, California. Entest officially took control of MAH on January 4, 2011. The McDonald Animal Hospital represents the first of several anticipated acquisitions by ENTB, and they are focusing on veterinary acquisition candidates in California. Thus, Entest has successfully completed its first move from a “emerging growth company” to a revenue producing business with significant upside potential from ImenVax™, which is the company's immuno-therapeutic cancer vaccine that utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure. ImenVax was outlined in our ENTB Report @ Waterville Research. ENTB stated in their recent 8-K filing that they:

“currently plan to raise additional funds by obtaining governmental and non-governmental grants as well as offering securities for cash.”

This can often cause concerns for investors, but people are starting to see that David Koos and his management team are delivering results with limited capital on hand. Assuming the Company has capital, ENTB should be in a stronger position.

After our comparison of ENTB versus WOOF, VCA Antech (WOOF) has traded down the past few days despite a strong overall market. We will continue to post updates on ENTB.

Entest BioMedical, Inc. (OTCBB: ENTB) - New Waterville Research Client

Entest BioMedical, Inc. (OTCBB: ENTB) is a biotechnology company focused on Veterinary Treatments that harness the animal’s reparative/ immunological mechanisms. Current market segments addressed by the Company’s treatments are:

1. Canine immuno-therapeutic cancer vaccines (dogs),
2. Expanded applications of immuno-therapeutic cancer vaccine for treating exotic species / zoo animals,
3. Development of Stem Cell related therapies for treating other veterinary maladies.

Entest also plans to acquire veterinary clinics for the marketing and distribution of its veterinary therapies. These clinics would provide immediate revenue and cash flow to fund development of the Company’s veterinary therapies. Entest believes it has the ability to self-fund R&D though internally generated cash flow.

Full Waterville Report @ ENTB Landing Page